TX-KAHUNA-WORKFORCE
6.2.2024 10:08:34 CET | Business Wire | Press release
Kahuna Workforce Solutions, the leading provider of skills and competency management software, has formed a strategic partnership with Norwegian operating services provider PXO AS to accelerate workforce competency in Norway’s booming energy sector, which is a significant stabilizer of the world’s oil and gas supply, particularly in meeting European demand.
The two companies, both of which already have established customers in Norway, have identified opportunities to jointly support the region’s growing demand for technically skilled professionals in the energy sector. The partnership specifically aims to improve operations readiness and assurance by combining Kahuna’s dynamic, digitized competency management platform with PXO’s extensive technical and field experience in a variety of operating production facilities offshore and onshore.
“PXO represents everything we look for in a partner as we strive to ensure successful and rapid adoption of competency-based training and development programs,” said Jai Shah, CEO of Kahuna Workforce Solutions. “As a company that works with many of the same customers as PXO, we’ve seen their expertise firsthand. It is clear they are the right partner to help us not only address the current needs of the energy industry but also pioneer innovative solutions that will shape the future of competency readiness and assurance in Norway.”
The collaboration comes at a critical time for the region, as Norway expects to draw nearly $22 billion in investments from oil and gas companies in 2024. The country is also leading the world toward cleaner energy solutions. Kahuna and PXO’s partnership will help Norwegian energy companies navigate this transition in a variety of ways, including streamlining skills validation and aligning operational standards with expanding ESG initiatives and emerging technologies.
“Just as we serve as a bridge between project and operation phases, Kahuna equips enterprises with validated competency data,” said Leif Olav Moe, CEO of PXO. “By uniting our technical and operational expertise with their cutting-edge competency management solutions, we are delivering a unique solution unlike anything the market has yet to provide—signifying our commitment to building a more skilled and competitive workforce to ascertain safer and more efficient operations.”
"At Kahuna, we are empowering organizations throughout the energy value chain by providing validated competency data and unique insights. This enables a deep understanding of workforce capabilities for seamless operational execution, in addition to aligning talent supply with demand and maximizing the return on investment in technical training,” Shah said. “When you combine our capabilities with PXO’s extensive experience in supporting operations with strategic training and competency services, there is no other competency management solution that comes close to building a skilled, safe, compliant, and competitive workforce.”
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
About PXO
PXO's services are mainly within the petroleum industry with field operating companies as clients, however, the services are also applied within other industry segments, such as shipping, renewable energy and aquaculture.
PXO increases awareness of safety barriers and their functions to improve efficiency and safety in field operations. Exposed to increasingly demanding requirements from authorities, clients, suppliers, and other stakeholders as regards knowledge and experience require systematic and targeted competence development of operations personnel in particular, extending from planning through construction & start-up and into regular operations. PXO ensures that prevailing competence requirements are met and followed up through various measures:
- Systematization of specific competence requirements
- Development of model-based interactive management tools (portal solutions)
- Harmonization of job descriptions and work processes
- Development and execution of training plans through interactive computer based training and practical On the Job Training (OJT) programmes.
PXO is focused on the interaction between people, organization and technology as a means to optimize, integrate and align work processes and technical equipment for robust and safe overall solutions.
For more information, visit https://www.pxo.no/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206626623/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom